Lite Strategy, Inc. Share Price

LITS

US55279B3015

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 15/10/2026 am IST			5-day change	1st Jan Change
1.170 ^USD	-3.31%		-7.87%	-11.36%

14/10	Lite Strategy, Inc. Launches Proof of Time Public Industry Archive	CI
29/09	Lite Strategy, Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI

Valuation: Lite Strategy, Inc.

Market Cap	3.56Cr 3.2Cr 2.99Cr 2.71Cr 5.08Cr 338.56Cr 5.11Cr 36Cr 14Cr 175.71Cr 13Cr 13Cr 565.14Cr	P/E 2025	-1.03x	P/E 2026	-0.45x
Enterprise Value	2.99Cr 2.69Cr 2.51Cr 2.27Cr 4.26Cr 284.26Cr 4.29Cr 30Cr 12Cr 147.53Cr 11Cr 11Cr 474.5Cr	EV / Sales 2025	-	EV / Sales 2026	-
Free-Float	86.21%	Yield 2025 *	-	Yield 2026	-

* Estimated data More valuation ratios

Latest news: Lite Strategy, Inc.

14/10	Lite Strategy, Inc. Launches Proof of Time Public Industry Archive	CI
29/09	Lite Strategy, Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI
30/07	Tranche Update on Lite Strategy, Inc.'s Equity Buyback Plan announced on October 29, 2025.	CI
29/06	Lite Strategy, Inc.(NasdaqCM:LITS) added to Russell Microcap Value Benchmark Index	CI
29/06	Lite Strategy, Inc.(NasdaqCM:LITS) added to Russell 3000E Index	CI
29/06	Lite Strategy, Inc.(NasdaqCM:LITS) added to Russell 3000E Value Benchmark	CI
29/06	Lite Strategy, Inc.(NasdaqCM:LITS) added to Russell Microcap Index	CI
18/06	ZK Innovations Inc. announced that it has received $1 million in funding from Lite Strategy, Inc.	CI
13/05	Tranche Update on Lite Strategy, Inc.'s Equity Buyback Plan announced on October 29, 2025.	CI
13/05	Lite Strategy, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
17/02	Lite Strategy, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025	CI
17/02	Tranche Update on Lite Strategy, Inc.'s Equity Buyback Plan announced on October 29, 2025.	CI
19/11	Lite Strategy Inc - On Nov 14, board approves Justin J. File as permanent CEO - SEC filing	RE

More news

Analysts' recommendations: Lite Strategy, Inc.

23/24/23	Laidlaw Downgrades MEI Pharma to Hold From Buy	MT
14/24/14	Stifel Adjusts Price Target on MEI Pharma to $7 From $8, Keeps Hold Rating	MT
27/23/27	Stifel Adjusts Price Target on MEI Pharma to $9 From $10, Maintains Hold Rating	MT
12/23/12	Stifel Adjusts MEI Pharma's Price Target to $10 From $0.50, Keeps Hold Rating	MT
13/23/13	Stifel Nicolaus Adjusts MEI Pharma Price Target to $0.50 From $2, Maintains Hold Rating	MT

More recommendations

Press Releases: Lite Strategy, Inc.

13/10	Lite Strategy Marks 15 Years of Litecoin with Launch of "Proof of Time" Public Industry Archive	GL
29/09	Lite Strategy Reports Fiscal Year 2026 Financial Results	GL
10/09	Lite Strategy to Present at the 28th Annual H.C. Wainwright Global Investment Conference in New York	GL
10/09	Lite Strategy to Present at the 28th Annual H.C. Wainwright Global Investment Conference in New York	AQ
30/07	Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share	GL

More press releases

News in other languages: Lite Strategy, Inc.

31/23/31	MÄRKTE USA/Wall Street von Wachstums- und Zinssorgen gedrückt
31/23/31	LATE BRIEFING - Unternehmen und Märkte
31/23/31	MÄRKTE USA/Wachstums- und Zinssorgen drücken Wall Street
31/23/31	MÄRKTE USA/Etwas leichter - Globale Wachstumssorgen belasten
31/23/31	MÄRKTE USA/Leichter - Anleger bleiben vorsichtig

More news

Managers and Directors: Lite Strategy, Inc.

Manager	Title	Age	Since
Justin File CEO	Chief Executive Officer	56	01/08/2024

Director	Title	Age	Since
Fred Driscoll CHM	Chairman	75	01/08/2024
Nick Glover BRD	Director/Board Member	57	11/06/2013
Justin File BRD	Director/Board Member	56	14/11/2025

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LITE STRATEGY, INC.	-3.31%	-7.87%	-46.58%	-82.54%	3.68Cr
WUXI APPTEC CO., LTD.	-2.01%	-7.86%	+60.74%	+70.97%	7.04TCr
ARGENX SE	+3.84%	-11.02%	+8.59%	+57.43%	5.03TCr
LONZA GROUP AG	+3.35%	+1.42%	+11.85%	+40.01%	4.75TCr
IQVIA HOLDINGS INC.	+0.51%	+1.51%	+27.96%	+31.43%	4.29TCr
REVOLUTION MEDICINES, INC.	+2.70%	-3.66%	+307.41%	+547.01%	4.04TCr
BEONE MEDICINES AG	+0.69%	-3.44%	+9.52%	+96.59%	3.97TCr
CELLTRION, INC.	+0.06%	-2.02%	+11.25%	+43.27%	3.06TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.95%	-12.28%	+43.51%	+1.30%	2.68TCr
BIONTECH SE	-0.39%	-6.92%	-13.60%	-14.40%	2.24TCr
Average	+0.25%	-6.02%	+42.06%	+79.11%	3.71TCr
Weighted average by Cap.	+0.76%	-4.90%	+55.17%	+102.68%

See all sector performances

Lite Strategy, Inc. is a pharmaceutical company focused on developed and differentiated cancer therapies. The Company's drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, zandelisib, an oral, once-daily, selective PI3Kd inhibitor. CDK9 functions in cell cycle regulation, and its modulation in cancer and autoimmune diseases. It is a transcriptional regulator of the myeloid leukemia cell differentiation protein (Mcl-1). Zandelisib is an oral, once-daily, selective PI3Kd inhibitor that is developed for the treatment of indolent B-cell lymphomas. Its approach to pre-clinical drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address medical needs. It holds Litecoin (LTC) tokens as a primary asset as part of an institutional treasury. LTC is an open source, global payment network that is decentralized without any central authorities.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/26/14	$1.170	-3.31%	2,78,822
13/26/13	$1.210	-0.82%	2,94,356
12/26/12	$1.220	-3.94%	2,71,264
09/26/09	$1.270	+4.10%	5,39,928
08/26/08	$1.220	-3.94%	9,82,810

Delayed Quote Nasdaq

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Lite Strategy, Inc.

Company calendar

1 day	-3.31%
1 week	-7.87%
Current month	-11.36%
1 month	+1.74%
3 months	+17.36%
6 months	+1.74%
Current year	-11.36%

1 week	1.15	1.3
1 month	0.99	1.54
Current year	0.69	1.65
1 year	0.69	2.26
3 years	0.69	9
5 years	0.69	71
10 years	0.69	102.8

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/02/26	Justin File	Free	Chief Executive Officer	4,55,000	1.2374%
19/12/25	James Flynn	Buy	Director	70,000	0.1903%
18/12/25	Alexander Schornstein	Sell		6,90,611	1.8774%

	2025	2026
Net sales	-	-
Net income	-1.59Cr -1.43Cr -1.34Cr -1.21Cr -2.28Cr -151.74Cr -2.29Cr -16Cr -6.27Cr -79Cr -5.99Cr -5.86Cr -253.29Cr	-7.12Cr -6.4Cr -5.97Cr -5.41Cr -10Cr -677.09Cr -10Cr -72Cr -28Cr -351.41Cr -27Cr -26Cr -1.13TCr
Net Debt	-1.8Cr -1.62Cr -1.51Cr -1.37Cr -2.57Cr -171.4Cr -2.59Cr -18Cr -7.08Cr -89Cr -6.76Cr -6.62Cr -286.11Cr	-57.06L -51.3L -47.88L -43.39L -81.47L -54Cr -81.97L -5.75Cr -2.24Cr -28Cr -2.14Cr -2.1Cr -91Cr

Lite Strategy, Inc. Share Price

Stocks

LITS

US55279B3015

Biotechnology & Medical Research

Valuation: Lite Strategy, Inc.

Chart: Lite Strategy, Inc.

Latest news: Lite Strategy, Inc.

Analysts' recommendations: Lite Strategy, Inc.

Press Releases: Lite Strategy, Inc.

News in other languages: Lite Strategy, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Lite Strategy, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Markets		Quality
Nasdaq	LITS	Delayed
CBOE	LITS	Real-time